Articles from these leading researchers, taken together, effectively paint the picture on a wide canvas and shine a spotlight on critical issues facing the translational oncology community. These leading experts provide a state-of-the-art assessment of timely questions spanning cancer research, from bedside to clinic (and back), including but not limited to accurate molecular assessment of genomic profiles, predictive and prognostic biomarkers, determination of appropriate treatments based on economic profiles, and also the financial toxicity stemming from the recent new wave of effective but expensive cancer-targeting therapies in lung cancer, breast cancer, colorectal cancer, and prostate cancer.
